AU2002347022A1 - Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten - Google Patents
Benzimidazols and indols as glucagon receptor antagonists/inverse agonistenInfo
- Publication number
- AU2002347022A1 AU2002347022A1 AU2002347022A AU2002347022A AU2002347022A1 AU 2002347022 A1 AU2002347022 A1 AU 2002347022A1 AU 2002347022 A AU2002347022 A AU 2002347022A AU 2002347022 A AU2002347022 A AU 2002347022A AU 2002347022 A1 AU2002347022 A1 AU 2002347022A1
- Authority
- AU
- Australia
- Prior art keywords
- benzimidazols
- agonisten
- indols
- inverse
- receptor antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101925 | 2001-12-20 | ||
DKPA200101925 | 2001-12-20 | ||
PCT/DK2002/000832 WO2003053938A1 (en) | 2001-12-20 | 2002-12-10 | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002347022A1 true AU2002347022A1 (en) | 2003-07-09 |
Family
ID=8160918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002347022A Abandoned AU2002347022A1 (en) | 2001-12-20 | 2002-12-10 | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002347022A1 (en) |
WO (1) | WO2003053938A1 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0203070D0 (en) * | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
WO2004063147A1 (en) * | 2003-01-10 | 2004-07-29 | Novo Nordisk A/S | Salts and solvates of glucagon antagonists |
AU2004210127B2 (en) | 2003-01-27 | 2009-10-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
US7563815B2 (en) | 2003-05-05 | 2009-07-21 | Merck & Co., Inc. | Benzamidazoles, compositions containing such compounds and methods of use |
SE0301698D0 (en) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0301699D0 (en) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
JP2007501189A (en) | 2003-08-01 | 2007-01-25 | ジェネラブス テクノロジーズ,インコーポレイテッド | Bicyclic imidazole derivatives for Flaviviridae |
DE602005006806D1 (en) | 2004-06-04 | 2008-06-26 | Merck & Co Inc | Pyrazole derivatives, compositions containing such compounds, and methods of use |
AU2005264915A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
AU2005264917A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
BRPI0511834A (en) | 2004-07-14 | 2008-01-08 | Ptc Therapeutics Inc | methods for treating hepatitis c |
NZ553329A (en) | 2004-07-22 | 2010-09-30 | Ptc Therapeutics Inc | Thienopyridines for treating hepatitis C |
DE602005021494D1 (en) | 2004-07-22 | 2010-07-08 | Merck Sharp & Dohme | SUBSTITUTED PYRAZOLE, SUCH COMPOUNDS AND COMPOSITIONS AND METHOD OF USE THEREOF |
KR100912146B1 (en) * | 2004-10-27 | 2009-08-14 | 에프. 호프만-라 로슈 아게 | New indole or benzimidazole derivatives |
EP2264036A1 (en) | 2005-01-14 | 2010-12-22 | Wyeth LLC (Formerly Known As Wyeth) | Amino-imidazolones for the inhibition of beta-secretase |
AU2006211159A1 (en) | 2005-02-01 | 2006-08-10 | Wyeth | Amino-pyridines as inhibitors of beta-secretase |
BRPI0606902A2 (en) | 2005-02-14 | 2009-07-28 | Wyeth Corp | compound; method for treating a disease or disorder associated with excessive baceous activity in a patient in need thereof; method for modulating bace activity; pharmaceutical composition |
EP1863755A1 (en) | 2005-03-21 | 2007-12-12 | Merck & Co., Inc. | Substituted aryl and heteroaryl derivatives |
JP2008534593A (en) | 2005-03-30 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | Glucagon receptor antagonist compounds, compositions containing such compounds, and methods of use thereof |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
WO2007005404A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
CN101300232A (en) | 2005-07-26 | 2008-11-05 | 默克公司 | Process for synthesizing a substituted pyrazole |
KR20080050430A (en) | 2005-09-26 | 2008-06-05 | 와이어쓰 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
TW200745031A (en) | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
JP2009001495A (en) * | 2005-10-13 | 2009-01-08 | Taisho Pharmaceutical Co Ltd | 2-aryl-benzimidazole-5-carboxamide derivative |
ATE442368T1 (en) | 2005-11-30 | 2009-09-15 | Hoffmann La Roche | 3-AMINO-2-ARYLPROPYLAZAINDOLE AND APPLICATIONS THEREOF |
WO2007062996A1 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles and aza-substituted indoles |
WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
EP2001472A2 (en) | 2006-03-23 | 2008-12-17 | Merck and Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
AU2007254329A1 (en) | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US7700606B2 (en) | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
KR20200123866A (en) | 2007-02-09 | 2020-10-30 | 메타베이시스 테라퓨틱스, 인크. | Novel antagonists of the glucagon receptor |
AR065814A1 (en) | 2007-03-23 | 2009-07-01 | Wyeth Corp | DERIVATIVES OF 5-PHENYLIMIDAZOLONE, INHIBITORS OF BETA-SECRETASA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES TO PREVENT AND / OR TREAT ASSOCIATED DISORDERS AT LEVELS BETA-AMYLOOES ELEVATED. |
PT2799428T (en) | 2008-08-13 | 2017-02-17 | Metabasis Therapeutics Inc | Glucagon antagonists |
SG191040A1 (en) | 2010-12-23 | 2013-08-30 | Pfizer | Glucagon receptor modulators |
WO2012107850A1 (en) | 2011-02-08 | 2012-08-16 | Pfizer Inc. | Glucagon receptor modulator |
EP2734503B1 (en) | 2011-07-22 | 2015-09-16 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
ES2702237T3 (en) | 2011-12-21 | 2019-02-28 | Allergan Inc | Compounds that act on multiple prostaglandin receptors that give a general anti-inflammatory response |
PL2897939T3 (en) * | 2012-09-21 | 2017-08-31 | Sanofi | Benzoimidazole-carboxylic acid amide derivatives for treating metabolic or cardiovascular diseases |
WO2015066252A1 (en) | 2013-11-04 | 2015-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions thereof, and methods of use |
WO2015191900A1 (en) | 2014-06-12 | 2015-12-17 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
CN107311933B (en) * | 2017-06-28 | 2020-12-22 | 中国人民解放军军事医学科学院毒物药物研究所 | Benzimidazole derivative, preparation method and application thereof |
WO2019160940A1 (en) | 2018-02-13 | 2019-08-22 | Ligand Pharmaceuticals Incorporated | Glucagon receptor antagonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1208323C (en) * | 1999-04-06 | 2005-06-29 | 三共株式会社 | Alpha-substituted carboxylic acid derivatives |
-
2002
- 2002-12-10 AU AU2002347022A patent/AU2002347022A1/en not_active Abandoned
- 2002-12-10 WO PCT/DK2002/000832 patent/WO2003053938A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003053938A1 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002347022A1 (en) | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten | |
AU2002314433A1 (en) | Ephrin-tie receptor materials and methods | |
AU2002365622A1 (en) | Novel glucagon antagonists | |
AU2001255798A1 (en) | Glucagon antagonists | |
AU2002341834A1 (en) | Antagonists | |
AU2003236205A1 (en) | Glucagon antagonists/inverse agonists | |
AU2003233780A1 (en) | Novel glucagon antagonists/inverse agonists | |
AU2002367424A1 (en) | Androgen receptor antagonists | |
AUPR769501A0 (en) | Cytokine receptor 1 | |
AU2002223501A1 (en) | Glucagon antagonists/inverse agonists | |
IL152700A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists | |
AU2002223500A1 (en) | Glucagon antagonists/inverse agonists | |
AU2001273032A1 (en) | Cytokine receptor zcytor17 | |
AU2001264657A1 (en) | Crf receptor antagonists | |
AU2003255501A1 (en) | Cxcr4 receptor antagonists | |
AU2002252460A1 (en) | Human cytokine receptor | |
AU2003291959A1 (en) | Novel glucagon antagonists | |
AU2002351730A1 (en) | Glucagon receptor antagonists/inverse agonists | |
IL159058A0 (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators | |
AU2002365655A1 (en) | 5-ht7 receptor antagonists | |
AU2002305944A1 (en) | Mouse cytokine receptor | |
AU2003225054A1 (en) | Toll-like receptor 11 and toll-like receptor 12 | |
AU2002359524A1 (en) | P2x7 receptor antagonists | |
AU2003206014A1 (en) | Neuropeptide receptor and uses thereof | |
AU2001277980A1 (en) | Human cytokine receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |